.
MergerLinks Header Logo

Announced

Completed

Croda completed the acquisition of Avanti Polar Lipids for $260m.

Financials

Edit Data
Transaction Value£208m
Consideration TypeCash, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Majority

lipid products

Acquisition

United States

Private

Specialty Chemicals

Friendly

Completed

Synopsis

Edit

Croda, a British speciality chemicals company, completed the acquisition of Avanti Polar Lipids, which manufactures and supplies lipid products, for $260m. "We have long admired the Avanti team for their deep scientific know-how and are already working together on high-potential commercial opportunities. With their exciting drug delivery technologies, Avanti is a market leader in a high growth niche of the health care market, serving over 3k customers globally. Bringing Avanti's best-in-class expertise into Croda also significantly enhances our presence across the pharma product lifecycle, including early stage R&D, clinical trials, analysis and formulation. I am confident that Avanti will prove transformative to the capabilities and performance of our Life Sciences sector," Steve Foots, Croda CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US